Artal Group’s TG Therapeutics TGTX Stock Holding History

Artal Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-511,389	Closed	-$7.69M	–	130
2023 Q1	$7.69M	Buy	+511,389	New	+$7.77M	0.46%	48
2022 Q2	–	Sell	-800,000	Closed	-$7.61M	–	142
2022 Q1	$7.61M	Hold	800,000	–	–	0.32%	62
2021 Q4	$15.2M	Hold	800,000	–	–	0.41%	53
2021 Q3	$26.6M	Hold	800,000	–	–	0.6%	41
2021 Q2	$31M	Sell	800,000 -700,000	-47%	-$27.5M	0.63%	35
2021 Q1	$72.3M	Hold	1,500,000	–	–	1.28%	21
2020 Q4	$78M	Hold	1,500,000	–	–	1.68%	17
2020 Q3	$40.1M	Sell	1,500,000 -250,000	-14%	-$5.75M	0.97%	26
2020 Q2	$34.1M	Buy	1,750,000 +750,000	+75%	+$12.1M	0.95%	29
2020 Q1	$9.84M	Buy	1,000,000 +350,000	+54%	+$4.42M	0.42%	48
2019 Q4	$7.21M	Sell	650,000 -250,000	-28%	-$1.9M	0.28%	58
2019 Q3	$5.05M	Hold	900,000	–	–	0.2%	72
2019 Q2	$7.79M	Buy	900,000 +100,000	+13%	+$756K	0.31%	62
2019 Q1	$6.43M	Buy	800,000 +400,000	+100%	+$2.16M	0.26%	67
2018 Q4	$1.64M	Hold	400,000	–	–	0.06%	96
2018 Q3	$2.24M	Hold	400,000	–	–	0.06%	98
2018 Q2	$5.26M	Buy	400,000 +150,000	+60%	+$2.06M	0.11%	65
2018 Q1	$3.55M	Sell	250,000 -150,000	-38%	-$1.92M	0.04%	83
2017 Q4	$3.28M	Hold	400,000	–	–	0.05%	80
2017 Q3	$4.74M	Sell	400,000 -100,000	-20%	-$1.14M	0.08%	64
2017 Q2	$5.03M	Buy	+500,000	New	+$5.6M	0.09%	64

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Artal Group's TGTX Position: Q2 2023 in Review

Artal Group sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 511,389 shares — an estimated $7.69M sold.

Artal Group first reported a position in TGTX in Q2 2017 and held it in 21 quarters. The position peaked at $78M in Q4 2020. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

Artal Group reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
Artal Group sold 511,389 TG Therapeutics shares in Q2 2023, an estimated $7.69M.
Artal Group first reported a position in TG Therapeutics in Q2 2017 and held it in 21 quarters.
Artal Group's TG Therapeutics position peaked at $78M in Q4 2020.
244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.